Zevra Therapeutics Q1 Earnings Call Highlights
MarketBeat
Zevra Therapeutics (NASDAQ:ZVRA) reported first-quarter 2026 net revenue of $36.2 million, up 78% from the prior-year period, as the company highlighted continued adoption of its Niemann-Pick disease type C (NPC) therapy MIPLYFFA in the U.S., growth in its global expanded access programs, and progre
NASDAQ:ZVRA